Comparative Pharmacology
Head-to-head clinical analysis: CYCLAFEM 0 5 35 versus LO LARIN FE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLAFEM 0 5 35 versus LO LARIN FE.
CYCLAFEM 0.5/35 vs LO LARIN FE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits gonadotropin release, suppressing ovulation. Increases cervical mucus viscosity and alters endometrium, reducing sperm penetration and implantation.
Combination of ethinyl estradiol (estrogen) and norethindrone (progestin) inhibits gonadotropin release, preventing ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial lining, reducing implantation likelihood.
One tablet (0.5 mg norethindrone/35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days (or no tablets) per cycle.
One tablet orally once daily for 28 consecutive days. Each tablet contains norethindrone acetate 1 mg and ethinyl estradiol 20 mcg. Active tablets (21 days) followed by ferrous fumarate 75 mg inert tablets (7 days).
None Documented
None Documented
Terminal elimination half-life of norethindrone is 5-14 hours (mean 7.6 hours); ethinyl estradiol half-life is 7-20 hours (mean ~13 hours). Steady-state is achieved within 5-7 days.
Ethinyl estradiol: ~13-17 hours; norethindrone: ~8-12 hours; steady-state achieved within 5-7 days; clinical significance: missed doses may require backup contraception.
Renal excretion accounts for approximately 50-60% of the dose (as metabolites), with 30-40% excreted in feces via biliary elimination. Unchanged drug is minimal in urine.
Renal: 30-50% as ethinyl estradiol metabolites and norethindrone metabolites; fecal: 30-50% primarily as norethindrone metabolites; biliary excretion contributes to enterohepatic circulation.
Category C
Category C
Oral Contraceptive
Oral Contraceptive